Invitro Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 29-06-2024
- Paid Up Capital ₹ 0.50 M
as on 29-06-2024
- Company Age 23 Year, 5 Months
- Last Filing with ROC 31 Mar 2020
- Satisfied Charges ₹ 0.80 M
as on 29-06-2024
- Revenue -32.92%
(FY 2020)
- Profit -743.23%
(FY 2020)
- Ebitda -299.39%
(FY 2020)
- Net Worth -95.79%
(FY 2020)
- Total Assets -65.75%
(FY 2020)
About Invitro Biotech
The Corporate was formerly known as Invitro Biotech Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹0.80 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jeniva Malik, Sujata Malik, and Chandra Malik serve as directors at the Company.
- CIN/LLPIN
U29219TG2001PLC037037
- Company No.
037037
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
18 Jul 2001
- Date of AGM
07 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Invitro Biotech Limited offer?
Invitro Biotech Limited offers a wide range of products and services, including Hospital Uniforms, Medical Apron, Laboratory & Lab Equipment, Laboratory Consumables, Medical Laboratory Instruments, Pathology Lab Equipments, Hematology Analyzers, Biochemistry Analyzer, Chemistry Analyzers, Laboratory Centrifuge.
Who are the key members and board of directors at Invitro Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujata Malik  | Director | 22-Jan-2016 | Current |
| Jeniva Malik | Director | 18-Jul-2001 | Current |
| Chandra Malik | Director | 18-Jul-2001 | Current |
Financial Performance of Invitro Biotech.
Invitro Biotech Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 32.92% decrease. The company also saw a substantial fall in profitability, with a 743.23% decrease in profit. The company's net worth observed a substantial decline by a decrease of 95.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Invitro Biotech?
In 2020, Invitro Biotech had a promoter holding of 55.00% and a public holding of 45.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 12 Nov 2001 | ₹0.80 M | Satisfied |
How Many Employees Work at Invitro Biotech?
Unlock and access historical data on people associated with Invitro Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Invitro Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Invitro Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
